Viewing Study NCT00538694


Ignite Creation Date: 2025-12-25 @ 1:31 AM
Ignite Modification Date: 2026-03-09 @ 7:22 AM
Study NCT ID: NCT00538694
Status: COMPLETED
Last Update Posted: 2019-11-14
First Post: 2007-10-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module References Module